AstraZeneca Fulvestrant Meets Primary Endpoint In Breast Cancer Late-stage Trial

(RTTNews) - AstraZeneca (AZN.L, AZN) announced positive results from the Phase III FALCON trial comparing fulvestrant 500mg to anastrozole 1mg for the treatment of locally-advanced or metastatic breast cancer, in postmenopausal women who have not had prior hormonal treatment for hormone receptor positive or HR+ breast cancer.

The company noted that Fulvestrant 500mg demonstrated superiority compared with anastrozole 1mg in FALCON, and met its primary endpoint of extended progression-free-survival. The trial showed an adverse event profile generally consistent with current knowledge of the safety profile of the medicines.

A full evaluation of the data is ongoing and the results are expected to be presented at a medical congress in 2016, the company said.

Aromatase inhibitors (such as anastrozole) are a standard of care in first-line treatment for postmenopausal women with advanced HR+ positive breast cancer.